The aim of the study was to evaluate the effects of simvastatin therapy on bone mineral density in hypercholesterolemic postmenopausal women. Fifty-three women, mean age 62,92 +6,08 years treated at the Institute for Treatment and Rehabilitation Niška Banja were included into this study. All patients were divided into two groups: I group - 32 women with total cholesterol level (Hol≥7,8 mmol/l) and II control group - 21 women with total cholesterol less than 7,8 mmol/l. Triglycerides (Tg), total cholesterol (Hol), HDL and LDL cholesterol (HDL-C and LDL-C) were determined. Bone mineral density (BMD) was determined on the lumbar spine (LlL4), by “LUNAR DPX” densitometer. The results were expressed as absolute values (g/cm2) and T score. All patients were treated with lifestyle and dietary modification, while patients in group I were treated with 20 mg of simvastat per day. Biochemical markers and bone mineral density were determined at the start and 12 months after. Simvastatin therapy 20mg⁄day significantly reduced Hol (-12,68%; p < 0,01) and LDL-C (-17,99%; p<0,005) levels after 12 months of follow-up. The concentration of TG and HDL-C showed insignificant changes. In II group, there were no significant changes in lipid parameters after 12 months of hypolipemic diet regimen. Increase in BMD +2,81%, (NS) was registered in I group, while decrease in BMD -3,45% (NS) was reported in II group. There was an inverse correlation between BMD changes and LDLC (r = -0,08; p = 0,686) in the patients on statin therapy compared to I group (r = 0,166, p = 0,626). Also, in the same group, an inverse correlation between BMD and Hol (r = 0,144; p = 0,476) was reported, which was similar to I group (r = -0,125; p = 0,715).These results did not reach statistical significance. Conclusion: Simvastatin therapy showed a positive trend and increase in bone mineral densisty in hypercholesterolemic posmenopausal women after 12 months of follow-up, however, without statistically significant difference.
References
1.
Rosa JC, J H, S V. Effect of statins on risk of coronary disease: A meta-analysis of rando mized controlled trials. JAMA. 1999;282:2340–6.
2.
Heart Protection Study Collaborative Group: MRC /BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20536 high risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22.
3.
Beek E, C L, Pluijm G. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone ex plants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res. 1999;14:722–9.
4.
Mundy G, Garrett R, Harris S. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946–9.
5.
A. RIRT, CP C. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial-Secondary analysis of a randomized controlled trial. Bone. 2005;37(190):191.
6.
Wang PS, Solomon DH, Mogun H. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283:3211–6.
7.
Chan KA, Andrade SE, Boles M. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185–8.
8.
Pasco JA, Kotowicz MA, Henry MJ. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537–40.
9.
Staa TP, S W, Vries F. Use of statins and risk of fractures. JAMA. 2001;285:1850–5.
10.
Reid IR, Hague W, Emberson J. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised contro lled trial. In: Long-term Intervention with Pravastatin in Ischaemic Disease Lancet 2001;357:509-12.
11.
Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. JAMA. 2000;284:1921–2.
12.
Kanis JA, Johnell O, Oden A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000;27:585–90.
13.
Adami S, Braga V, Gatti D. Association between bone mineral density and serum lipids in men. JAMA. 2001;286:791–2.
14.
Chung YS, Lee MD, Lee SK. HMG-CoA redu ctase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 2000;85:1137–42.
15.
Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355:2218–9.
16.
Watanabe S, Fukumoto S, Takeuchi Y. Effects of 1-year treatment with Fluvastatin or Pravastatin on bone. Am J Med. 2001;110:584–7.
17.
Montagnani A, Gonnelli S, Cepollaro C. Effect of Simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal stu dy. 2003;32:427–33.
18.
Rejinmark L, Buus NH, Vestergaard P. Statins decrease bone turnover in postmenopausal women: A cross sectional study. Eur J Clin Invest. 2002;32:581–9.
19.
Hatzigeorgiou CĆ, Jackson JL. Hydroxymethyl-gluta ryl-coenzyme A reductase inhibitors and osteoporo sis: a meta-analysis. Osteoporosis Int. 2005;16:990–8.
20.
Lane NE, Rehman Q. Osteoporosis in the rheumatic disease patient. Lupus. 2002;11:675–9.
21.
Satyawan BJ, Girish KJ. Statins and osteoporosis. JPP. 2006;58:3–18.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
